IntelliPharmaCeutics Spikes Over 12% Higher on Settlement for Generic Version of Effexor

by Benzinga Staff

June 21, 2011 1:38 PM | 20 seconds read | Make a Comment

IntelliPharmaCeutics

IPCI

spikes over 12% higher on the settlement for a generic version of Effexor. The company was granted a non-exclusive license to the patents in suit that will permit Intellipharmaceutics to launch a generic of Effexor XR in the United States following U.S. Food and Drug Administration approval of this product. IntelliPharmaCeutics is currently trading at $3.85 per share.

Market News and Data brought to you by Benzinga APIs

Posted In: Intraday Update

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!